Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Husain, Hatim
NCT04545710: Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance	Active, not recruiting	2	18	US	Abemaciclib, Verzenios, Osimertinib, Tagrisso	University of California, San Diego, Eli Lilly and Company	Lung Cancer	12/25	12/26
NCT04043195: Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC	Active, not recruiting	1/2	30	US	Nivolumab, Opdivo, Oxaliplatin, Eloxatin, Ipilimumab, Yervoy	Hatim Husain	Advanced NSCLC	12/25	12/26
Yang, Hannah
No trials found